SAB Biotherapeutics (SABS) Share-based Compensation (2021 - 2026)

SAB Biotherapeutics has reported Share-based Compensation for 6 years, with the latest figure at $5.5 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation rose 790.76% year-over-year to $5.5 million; the trailing twelve-month figure through Mar 2026 stood at $10.1 million (up 242.41% YoY), and the FY2025 full-year result was $5.2 million, up 77.12% from the prior year.
• Share-based Compensation for Q1 2026 stood at $5.5 million, up from $3.2 million in the prior quarter.
• The five-year high for Share-based Compensation was $5.5 million in Q1 2026, with the low at $569861.0 in Q2 2022.
• Historically, Share-based Compensation has averaged $1.2 million across 5 years, with a median of $639246.0 in 2023.
• Annual changes were most pronounced in 2024 — Share-based Compensation sank 66.2% — and 2026, when it jumped 790.76%.
• SAB Biotherapeutics' Share-based Compensation stood at $628540.0 in 2022, then jumped by 217.36% to $2.0 million in 2023, then sank by 66.2% to $674135.0 in 2024, then jumped by 370.19% to $3.2 million in 2025, then surged by 72.25% to $5.5 million in 2026.
• The last three Share-based Compensation figures came in at $5.5 million (Q1 2026), $3.2 million (Q4 2025), and $800764.0 (Q3 2025), per Business Quant data.